2017-10-17 13:06:38 UTC

How Will Translational Advances in Pediatric IBD Affect Practices?

Oct. 17, 2017

Dr. Rosen will discuss how new findings can make a difference for pediatric IBD patients at the Crohn’s & Colitis Congress.

In the past year there have been tremendous translational advances in our understanding of the biology of pediatric inflammatory bowel disease (IBD) that will have important implications for how to assess IBD phenotype, predict treatment response and stratify therapy for  patients. 

Hear Michael Rosen, MD, MSCI, Cincinnati Children's Hospital Medical Center, as he critically assesses these studies and discusses how these findings can be applied to clinical practice to make a difference for pediatric patients. Register for AGA and the Crohn's & Colitis Foundation's Crohn's & Colitis Congress™, Jan. 18-20, 2018, in Las Vegas and add-on the Pre-Congress Workshop: Cutting-Edge Pediatric IBD to attend Dr. Rosen's session Translational Advances in Pediatric IBD – How Will It Affect My Practice? 

More on Crohn's Disease

Blog: What Happens When Patients With Crohn’s Disease in Remission Stop Taking Infliximab?

Feb. 21, 2018

Researchers report that fewer than one-fifth of patients required surgery. Read more on the AGA Journals Blog.

Attend the AGA Postgraduate Course for Practical, Take Home Information

Feb. 12, 2018

Join us on June 2-3 in Washington, D.C. This course is held in conjunction with Digestive Disease Week® (DDW) 2018.

Building an IBD Specialty Clinic from the Ground Up

Feb. 7, 2018

Gastro One in Tennessee developed an IBD clinic within their practice, which decreased emergency room visits by 70 percent.